Abstract
We previously screened neurite outgrowth activities of several Ginseng drugs in human neuroblastoma, and demonstrated that protopanaxadiol (ppd)-type saponins were active constituents. Since ppd-type saponins are known to be completely metabolized to 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (M1) by intestinal bacteria when taken orally, M1 and ginsenoside Rb1, as a representative of ppd-type saponins, were examined for cognitive disorder. In a mouse model of Alzheimer's disease (AD) by Aβ(25–35) i.c.v. injection, impaired spatial memory was recovered by p.o. administration of ginsenoside Rb1 or M1. Although the expression levels of phosphorylated NF-H and synaptophysin were reduced in the cerebral cortex and the hippocampus of Aβ(25–35)-injected mice, their levels in ginsenoside Rb1- and M1-treated mice were almost completely recovered up to control levels. Potencies of the effects were not different between ginsenoside Rb1 and M1 when given orally, suggesting that most of the ginsenoside Rb1 may be metabolized to M1, and M1 is an active principal of ppd-type saponins for the memory improvement. In cultured rat cortical neurons, M1 showed extension activity of axons, but not dendrites. The axon-specific outgrowth was seen even when neuritic atrophy had already progressed in response to administration of Aβ(25–35) as well as in the normal condition. These results suggest that M1 has axonal extension activity in degenerated neurons, and improve memory disorder and synaptic loss induced by Aβ(25–35). M1 was shown to be effective in vitro and in vivo, indicating that Ginseng drugs containing ppd-type saponins may reactivate neuronal function in AD by p.o. administration.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Casley CS, Land JM, Sharpe MA, Clark JB, Duchen MR, Canevari L (2002). Amyloid fragment 25–35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 10: 258–267.
Chan-Palay V (1991). Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res 88: 625–630.
DeKosky ST, Scheff SW (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27: 457–464.
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C et al (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523–527.
Geddes JW, Anderson KJ, Cotman CW (1986). Senile plaques as aberrant sprout-stimulating structures. Exp Neurol 94: 767–776.
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW et al (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183–195.
Grace EA, Busciglio J (2003). Aberrant activation of focal adhesion proteins mediates fibrillar amyloid β-induced neuronal dystrophy. J Neuro Sci 23: 493–502.
Grace EA, Rabiner CA, Busciglio J (2002). Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. J Neurosci 114: 265–273.
Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P et al (1987). A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett 73: 192–196.
Hasegawa H, Sung J-H, Benno Y (1997). Role of human intestinal Prevotella oris in hydrolyzing Ginseng saponins. Planta Med 63: 436–440.
Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljarvi L, Koivisto E et al (1995). Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience 64: 375–384.
Ikegaya Y, Matsuura S, Ueno S, Baba A, Yamada MK, Nishiyama N et al (2002). Amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J Biol Chem 277: 32180–32186.
Karikura M, Miyase T, Tanizawa H, Taniyama T, Takino Y (1991). Studies on absorption, excretion and metabolism of Ginseng saponons. VII. Comparison of the decomposition of ginsenoside-Rb1 and -Rb2 in the digestive tract of rats. Chem Pharm Bull 39: 2357–2361.
Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT et al (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22: 6331–6335.
Lin H, Bhatia R, Lal R (2001). Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15: 2433–2444.
Mook-Jung I, Hong HS, Boo JH, Lee KH, Yun SH, Cheong MY et al (2001). Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J Neurosci Res 63: 509–515.
Nishiyama N, Cho SI, Kitagawa I, Saito H (1994). Malonylginsenoside Rb1 potetiated nerve growth factor (NGF)-induced neurite outgrowth of cultured chick embryonic dorsal root ganglia. Biol Pharm Bull 17: 509–513.
Odani T, Tanizawa H, Takino Y (1983). Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. III. The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem Pharm Bull 31: 1059–1066.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39: 409–421.
Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000). Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22: 89–95.
Postuma RB, He W, Nunan J, Beyreuther K, Masters CL, Barrow CJ et al (2000). Substrate-bound beta-amyloid peptides inhibit cell adhesion and neurite outgrowth in primary neuronal cultures. J Neurochem 74: 1122–1130.
Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK et al (1999). Trophic effects of purines in neurons and glial cells. Prog Neurobiol 59: 663–690.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136–145.
Saito H, Suda K, Schwab M, Thoenen H (1977). Potentiation of the NGF-mediated nerve fiber outgrowth by ginsenoside Rb1 in organ cultures of chicken dorsal root ganglia. Jpn J Pharmacol 27: 445–451.
Sugaya A, Yuzurihara M, Tsuda T, Yasuda K, Kajiwara K, Sugaya E (1988). Proliferative effect of ginseng saponin on neurite extension of primary cultured neurons of the rat cerebral cortex. J Ethnopharmacol 22: 173–181.
Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M (2003). Degeneration of ginsenosides in humans after oral administration. Drug Metab Dispos 31: 1065–1071.
Tohda C, Matsumoto N, Zou K, Meselhy RM, Komatsu K (2002). Axonal and dendritic extension by protopanaxadiol-type saponins from Ginseng drugs in SK-N-SH cells. Jpn J Pharmacol 90: 254–262.
Tohda C, Tamura T, Komatsu K (2003). Repair of amyloid β(25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res 990: 141–147.
Valouskova V, Gschanes A (1999). Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short- and long-term study. Neurobiol Learn Mem 71: 132–149.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535–539.
Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE et al (2002). Peroxynitrite mediates neurotoxicity of amyloid β-peptide 1-42 and lipopolysaccharide-activated microglia. J Neuro sci 22: 3484–3492.
Yamada K, Nabeshima T (2000). Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 88: 93–113.
Zhao R, McDaniel WF (1998). Ginseng improves strategic learning by normal and brain-damaged rats. Neuroreport 9: 1618–1624.
Zhong YM, Nishijo H, Uwano T, Tamura R, Kawanishi K, Ono T (2000). Red ginseng ameliorated place navigation deficits in young rats with hippocampal lesions and aged rats. Physiol Behav 69: 511–525.
Acknowledgements
This work was supported by Kampou Science Foundation, Uehara Memorial Foundation, a Grant-in-Aid for Scientific Research (B), No. 11695086 in 1999–2001 from the Japan Society for the Promotion of Science, and a Grant-in-Aid for the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tohda, C., Matsumoto, N., Zou, K. et al. Aβ(25–35)-Induced Memory Impairment, Axonal Atrophy, and Synaptic Loss are Ameliorated by M1, A Metabolite of Protopanaxadiol-Type Saponins. Neuropsychopharmacol 29, 860–868 (2004). https://doi.org/10.1038/sj.npp.1300388
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300388
Keywords
This article is cited by
-
Kamikihito reduces β-amyloid25–35-induced axon damage via neurotrophic factors
Journal of Natural Medicines (2024)
-
Prevention of colistin-induced neurotoxicity: a narrative review of preclinical data
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Aβ25–35 Suppresses Mitochondrial Biogenesis in Primary Hippocampal Neurons
Cellular and Molecular Neurobiology (2016)
-
The neuritogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells
BMC Complementary and Alternative Medicine (2015)
-
Herbal medicine in the treatment of Alzheimer’s disease
Chinese Journal of Integrative Medicine (2015)
